Litigation Details for TAKEDA PHARMACEUTICAL COMPANY LIMITED v. WOCKHARDT BIO AG (D.N.J. 2013)

TAKEDA PHARMACEUTICAL COMPANY LIMITED v. WOCKHARDT BIO AG (D.N.J. 2013)

Docket		Date Filed	2013-10-25
Court	District Court, D. New Jersey	Date Terminated	2017-06-30
Cause	35:271 Patent Infringement	Assigned To	Mary Little Cooper
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Patents	6,328,994; 7,399,485; 7,431,942; 7,875,292
Link to Docket	External link to docket

Details for TAKEDA PHARMACEUTICAL COMPANY LIMITED v. WOCKHARDT BIO AG (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-25				External link to document

Litigation summary and analysis for: TAKEDA PHARMACEUTICAL COMPANY LIMITED v. WOCKHARDT BIO AG (D.N.J. 2013)

Last updated: May 23, 2026

TAKEDA v. Wockhardt BIO AG (3:13-cv-06427): Litigation Summary, Patent Scope, Timeline, and Commercial Impact

Executive summary: The U.S. federal case Takeda Pharmaceutical Company Limited v. Wockhardt Bio AG, docket 3:13-cv-06427, is a patent infringement dispute tied to Takeda’s branded product and Wockhardt’s biosimilar or follow-on development plans. The record reflects a postures typical of FDA BLA/ANDA-adjacent biologic disputes, with the core litigation risk centered on whether Wockhardt’s proposed product infringes Takeda’s asserted claims and whether asserted claims are invalid or unenforceable.

Actionable bottom line: For licensing, generic/biosimilar entry timing, and settlement leverage, the main decision points are (1) which Takeda patents were asserted and survived dispositive motions, (2) the claim constructions applied by the court, and (3) whether any final judgment or stipulation enabled an FDA pathway approval earlier than the asserted patent expiration.

Key limitation: A complete litigation summary (asserted patents list, claim numbers, rulings, settlement terms, and final judgment dates) requires docket-specific filings and court orders that are not present in the prompt content.

---

What patents were asserted in Takeda Pharmaceutical Company Limited v. Wockhardt Bio AG (3:13-cv-06427)?

Featured snippet answer: The asserted patent set cannot be identified from the provided information, so the patent estate scope for this specific docket cannot be stated accurately.

Which Takeda patents were in suit?

A full, correct answer depends on the Complaint and any Amended Complaint listing the asserted U.S. patents and claims.

Which Wockhardt products or biosimilar candidates were at issue?

The product identification also requires the Complaint and any sublicensing or infringement allegations tied to the proposed label.

Jurisdiction and case posture

The case number indicates a U.S. District Court action, but the provided prompt does not include:

• the assigned district judge,
• the venue,
• the court dates for Markman and dispositive motion practice,
• or whether the case includes Hatch-Waxman-style timing frameworks (for ANDAs) or BPCIA-style provisions (for BLAs).

---

When did Takeda v. Wockhardt Bio AG (3:13-cv-06427) start, and what was the procedural timeline?

Featured snippet answer: The filing year “2013” aligns with typical sequence structures (initial filing, responsive pleadings, claim construction, summary judgment, trial or settlement). However, the exact timeline for this docket cannot be extracted from the prompt.

Milestones typically tracked in these disputes

Without the docket orders, these cannot be mapped to dates for 3:13-cv-06427:

• Initial complaint filing and service date
• Answer, motions to dismiss, and amended pleadings
• Markman (claim construction) hearing and order date
• Summary judgment schedule and rulings
• Trial date(s)
• Final judgment or voluntary dismissal with prejudice
• Settlement-related filings, if any

---

How strong is the patent estate for Takeda in 3:13-cv-06427?

Featured snippet answer: Strength cannot be quantified for this specific case without:

• the number of asserted patents,
• the asserted claims,
• the court’s construction and validity holdings,
• and whether any patents were dropped.

What drives enforceability in this docket

For high-stakes evaluations, the key inputs are:

• claim construction outcomes (literal infringement scope vs equivalents),
• prior art and obviousness standards used by the court,
• priority dates and prosecution history estoppel effects,
• enforceability defenses (inequitable conduct, enablement, written description),
• and whether any asserted claims were invalidated.

---

What claim construction outcomes mattered most in Takeda v. Wockhardt Bio AG?

Featured snippet answer: Claim construction outcomes are not available in the provided prompt content.

Claim construction impact on infringement

In patent disputes of this type, claim constructions typically determine:

• whether the accused product meets “structural/functional” limitations,
• whether manufacturing or formulation processes fall within method claims,
• and how broad the construed terms are for infringement analysis.

---

Did the court find infringement or invalidate any asserted claims in 3:13-cv-06427?

Featured snippet answer: The prompt contains no rulings or final disposition.

Possible end states and what they mean commercially

Common outcomes in these cases:

• claim-by-claim infringement findings with injunction risk,
• partial summary judgment with residual issues,
• invalidity rulings that remove injunction leverage,
• dismissal/settlement that changes FDA entry timing,
• post-trial judgment affecting royalty or licensing terms.

---

What settlement agreements or consent judgments affected entry timing for Wockhardt?

Featured snippet answer: No settlement or consent judgment terms are present in the prompt content.

Settlement terms that change the business outcome

For biosimilar/generic launch planning, the terms that matter are:

• license scope (country and product boundaries),
• royalty rate and payment triggers,
• “carve-outs” (formulation changes, dosage changes, label scope),
• exclusivity carve-ins tied to regulatory milestones,
• and non-admission and termination provisions.

---

How does this case affect FDA biosimilar or generic approval strategy for Wockhardt?

Featured snippet answer: The FDA regulatory linkage for this docket cannot be determined from the prompt.

What to look for in the FDA linkage

In practice, the litigation impacts:

• whether a court order blocks approval,
• whether “at-risk” launch becomes rational,
• whether settlement triggers earlier approval or delayed launches,
• and whether certain patent listings in Orange Book or BPCIA patent lists drive 180-day/other timing frameworks.

---

What is the Orange Book or BPCIA listing status relevant to 3:13-cv-06427?

Featured snippet answer: Orange Book/BPCIA listing status cannot be provided accurately because the asserted patents and the branded reference product are not identified in the prompt.

Why listing status matters

Patent listings determine:

• the statutory triggers for litigation timelines,
• whether Wockhardt’s challenge type (e.g., Paragraph IV) is available,
• and the scope of available statutory remedies.

---

Which companies are challenging Takeda’s patents in this litigation and how does it compare with other Takeda disputes?

Featured snippet answer: The prompt identifies only Takeda and Wockhardt Bio AG. Comparatives to other challenges require additional docket and case data.

Typical competitor landscape variables

Business relevance usually depends on:

• whether multiple generics/biosimilars target the same reference product,
• whether they share common technical infringement positions,
• whether they used similar “non-infringement by design” strategies,
• and whether Takeda obtained consistent claim constructions across cases.

---

What formulations or delivery systems are implicated in Takeda v. Wockhardt Bio AG?

Featured snippet answer: The prompt does not include the product, dosage form, or formulation-specific allegations, so formulation scope cannot be stated.

Why formulation scope often drives infringement

In these cases, infringement can turn on:

• excipient composition and functional roles,
• specific device/administration constraints,
• particle size and stability parameters,
• and manufacturing controls tied to functional product characteristics.

---

Key takeaways

• The provided information identifies the parties and docket number only: Takeda Pharmaceutical Company Limited v. Wockhardt Bio AG, 3:13-cv-06427.
• A litigation summary that includes asserted patents, claim numbers, claim constructions, infringement/validity outcomes, settlement terms, and final disposition cannot be produced from the prompt content.
• For downstream business decisions (entry timing, licensing value, litigation risk), the next operational step is extracting the Complaint/Amended Complaint, Markman order(s), summary judgment orders, and the final judgment or dismissal order from the docket.

---

FAQs

1. What is the exact court and judge assignment for 3:13-cv-06427?
2. Which specific U.S. patents and claims does Takeda assert in this docket?
3. What Markman claim constructions were issued and how do they narrow infringement scope?
4. Did the court enter an injunction, dismiss the case, or approve a settlement-driven dismissal?
5. How does the outcome of 3:13-cv-06427 change biosimilar or generic entry timing for Wockhardt’s candidate?

---

References

(APA)
No sources are included because no docket filings, orders, or external citations were provided in the prompt content.